Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-29
2007-05-29
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S079000
Reexamination Certificate
active
10485515
ABSTRACT:
The invention provides compounds of the formula (I), in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.
REFERENCES:
patent: 4468400 (1984-08-01), Gold et al.
patent: WO 95/27714 (1995-10-01), None
patent: WO 98/42707 (1998-10-01), None
patent: WO 98/54188 (1998-12-01), None
patent: WO01/72757 (2001-10-01), None
Kaminski, J.J. et al. “Antiulcer Agents. 5. Inhibition of Gastric H+/K+-ATPase by Substituted Imidazo [1, 2-a] pyridines and Related Analogues and Its Implication in Modeling the High Affinity Potassium Ion Binding Site of the Gastric Proton Pump Enzyme”, J. Med. Chem., vol. 34 pp. 533-541, 1991.
Kaminski, J.J. et al. “Antiulcer Agents. 4. Conformational Considerations and the Antiulcer Activity Substituted Imidazo [1, 2-a] pyridines and Related Analogues”,J.Med.Chem.,vol. 32 pp. 1686-1700, 1989.
Buhr Wilm
Senn-Bilfinger Jörg
Altana Pharma AG
Desai Rita
Goldberg Joshua B.
McGee Sheldon M.
The Nath Law Group
LandOfFree
Tricyclic imidazopyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic imidazopyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic imidazopyridines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3824786